Lilly Bolsters Diabetes Pipeline with KeyBioScience Collaboration
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 6 (Table of Contents)
Published: 22 Jun-2017
DOI: 10.3833/pdr.v2017.i6.2258 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Eli Lilly has added to its early-stage diabetes pipeline by collaborating with KeyBioScience AG and gaining a worldwide licence to develop the Swiss company’s dual amylin calcitonin receptor agonists (DACRAs), a potential new class of treatments for metabolic disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS